Why the study?
Does platelet function testing to time surgery improve bleeding and ischemic outcomes compared to a fixed waiting period in patients on P2Y12 inhibitors?
Does platelet function testing to time surgery improve bleeding and ischemic outcomes compared to a fixed waiting period in patients on P2Y12 inhibitors?
While platelet function testing may offer a personalized approach to timing surgery in patients on P2Y12 inhibitors, large-scale trials are still needed to define optimal assays and cutoffs.
Platelet function testing should not yet guide surgical timing on P2Y12 inhibitors; leaves open optimal assay and cutoff definition by large trials.
In patients pretreated with P2Y12 receptor inhibitors who need to undergo non-emergent cardiac or major non-cardiac surgery, current guidelines of the European Society of Cardiology recommend postponing surgery for at least five days after last intake of clopidogrel or ticagrelor, and for seven days after last intake of prasugrel, unless there is high risk of ischemic events. However, a fixed five to seven days preoperative waiting period may be challenged, in the presence of inter-individual variability in on-treatment platelet reactivity. Therefore, Society of Thoracic Surgeons guidelines suggest to base decisions about a surgical delay on platelet function although both, the optimal platelet function assay and a bleeding cutoff have not yet been defined by large scale multicenter trials. This review aims to provide an overview on current knowledge of P2Y12 receptor induced platelet inhibition and surgery related bleeding and the potential role of platelet function analysis to time surgery.
No takes yet. Share an insight, caveat, or question.
Raggam et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: